Hikal Limited
NSE: HIKAL BSE: HIKAL
NSE
195.69
9.13 (4.89%)
Prev Close
186.56
Open Price
194.09
Volume
379,109
Today Low / High
192.79 / 199.44
52 WK Low / High
182 / 456.75
Range
186 - 205
BSE
194.60
7.40 (3.95%)
Prev Close
187.2
Open Price
200
Volume
11,137
Today Low / High
192.95 / 200
52 WK Low / High
182.5 / 456.6
Range
185 - 204
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 195.69 (target range: 186 - 205), reflecting a change of 9.13 (4.89387%). On the BSE, it is listed at 194.6 (target range: 185 - 204), showing a change of 7.4 (3.95299%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
03 Feb
194.09
0.64%
02 Feb
190.10
-1.86%
01 Feb
192.99
-1.49%
30 Jan
189.10
1.84%
29 Jan
197.60
-3.33%
28 Jan
194.05
1.03%
27 Jan
194.56
-0.44%
23 Jan
199.78
-2.61%
22 Jan
202.00
-1.20%
21 Jan
205.72
-2.60%
20 Jan
210.98
-1.49%
19 Jan
209.67
1.20%
16 Jan
209.11
0.27%
14 Jan
211.35
0.26%
13 Jan
214.37
-0.72%
12 Jan
211.26
1.73%
09 Jan
219.01
-1.60%
08 Jan
224.76
-2.88%
07 Jan
224.70
-0.85%
06 Jan
226.20
-1.35%
Hikal Limited Graph
Hikal Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Hikal Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 195.69, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 194.60 | 196.55 | 176.89 - 216.20 |
| 198.49 | 158.79 - 238.19 | ||
| 200.44 | 140.31 - 260.57 | ||
| Bearish Scenario | 194.60 | 192.65 | 173.39 - 211.92 |
| 190.71 | 152.57 - 228.85 | ||
| 188.76 | 132.13 - 245.39 |
Overview of Hikal Limited
ISIN
INE475B01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,570,800
Market Cap
24,128,723,768
Last Dividend
1.4
Official Website
IPO Date
2002-07-01
DCF Diff
64.12
DCF
131
Financial Ratios Every Investor Needs
Stock Dividend of HIKAL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-02 | September 02, 25 | 0.8 | 0.8 | 2025-09-02 | 2025-10-23 | |
| 2025-02-07 | February 07, 25 | 0.6 | 0.6 | 2025-02-08 | 2025-03-05 | |
| 2024-09-04 | September 04, 24 | 0.6 | 0.6 | 2024-09-04 | 2024-10-17 | |
| 2024-02-20 | February 20, 24 | 0.6 | 0.6 | 2024-02-20 | 2024-03-09 | |
| 2023-09-18 | September 18, 23 | 0.6 | 0.6 | 2023-09-19 | 2023-10-26 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,859.80 Cr | 837.30 Cr | 1,022.50 Cr | 0.5498 | 77.50 Cr | 248.70 Cr | 775.40 Cr | 90.80 Cr | 7.36 | 333.40 Cr | 0.0488 |
| 2024-03-31 | 1,768.66 Cr | 864.03 Cr | 904.62 Cr | 0.5115 | 73.43 Cr | 61.44 Cr | 149.42 Cr | 69.60 Cr | 5.64 | 267.03 Cr | 0.0394 |
| 2023-03-31 | 2,004.71 Cr | 1,142.27 Cr | 862.44 Cr | 0.4302 | 70.84 Cr | 57.07 Cr | 148.93 Cr | 78.38 Cr | 6.36 | 259.93 Cr | 0.0391 |
| 2022-03-31 | 1,926.03 Cr | 1,042.61 Cr | 883.42 Cr | 0.4587 | 61.94 Cr | 42.62 Cr | 245.24 Cr | 160.50 Cr | 13.02 | 340.42 Cr | 0.0833 |
| 2021-03-31 | 1,707.05 Cr | 936.64 Cr | 770.41 Cr | 0.4513 | 53.07 Cr | 22.53 Cr | 229.49 Cr | 133.14 Cr | 10.80 | 323.62 Cr | 0.0780 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 13.00 Cr | 2,528.90 Cr | 1,266.60 Cr | 1,262.3000 Cr | 764.70 Cr | 746.70 Cr | 334.50 Cr | 1,477.90 Cr | 0.00 Cr | 59.30 Cr | 9.50 Cr | 789.5000 Cr |
| 2024-03-31 | 12.70 Cr | 2,487.14 Cr | 1,299.49 Cr | 1,187.6610 Cr | 817.58 Cr | 804.87 Cr | 303.72 Cr | 1,483.00 Cr | 0.00 Cr | 59.35 Cr | 0.40 Cr | 756.6330 Cr |
| 2023-03-31 | 26.73 Cr | 2,385.48 Cr | 1,252.01 Cr | 1,133.4700 Cr | 748.18 Cr | 721.45 Cr | 316.74 Cr | 1,377.57 Cr | 18.29 Cr | 43.64 Cr | -8.61 Cr | 661.5540 Cr |
| 2022-03-31 | 11.44 Cr | 2,213.11 Cr | 1,145.13 Cr | 1,067.9810 Cr | 675.02 Cr | 663.58 Cr | 328.98 Cr | 1,184.76 Cr | 40.82 Cr | 29.00 Cr | 1.36 Cr | 769.1820 Cr |
| 2021-03-31 | 7.64 Cr | 1,913.22 Cr | 979.82 Cr | 933.4020 Cr | 610.25 Cr | 602.61 Cr | 266.70 Cr | 973.49 Cr | 5.18 Cr | 0.00 Cr | -4.05 Cr | 656.7850 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 280.4000 Cr | -136.5000 Cr | -143.6000 Cr | 143.1000 Cr | 0.3000 Cr | 13.0000 Cr | -137.3000 Cr | 90.8000 Cr | -53.5000 Cr | -14.8000 Cr | -32.4000 Cr |
| 2024-03-31 | 186.7200 Cr | -173.7450 Cr | -27.0000 Cr | -17.4800 Cr | -14.0270 Cr | 12.7030 Cr | -204.1960 Cr | 95.5050 Cr | 66.5230 Cr | -14.8270 Cr | 11.0200 Cr |
| 2023-03-31 | 315.3090 Cr | -292.3400 Cr | -7.6800 Cr | 12.6890 Cr | 15.2890 Cr | 26.7300 Cr | -302.6200 Cr | 105.3650 Cr | 69.4890 Cr | -12.3300 Cr | 8.2330 Cr |
| 2022-03-31 | 293.7330 Cr | -284.3710 Cr | -5.5580 Cr | 20.4190 Cr | 3.8040 Cr | 11.4000 Cr | -273.3140 Cr | 218.5590 Cr | 66.7470 Cr | -27.1260 Cr | -63.4200 Cr |
| 2021-03-31 | 229.0180 Cr | -156.1960 Cr | -96.8680 Cr | 71.4190 Cr | -24.0470 Cr | 7.6360 Cr | -157.5990 Cr | 206.4250 Cr | -32.9520 Cr | -14.8190 Cr | 39.7650 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 316.20 Cr | 126.30 Cr | 189.90 Cr | 0.6006 | -34.00 Cr | -34.90 Cr | -2.83 | 9.10 Cr | -0.1104 |
| 2025-06-30 | 371.30 Cr | 186.80 Cr | 184.50 Cr | 0.4969 | -14.30 Cr | -22.40 Cr | -1.82 | 26.10 Cr | -0.0603 |
| 2025-03-31 | 552.40 Cr | 232.20 Cr | 320.20 Cr | 0.5797 | 256.80 Cr | 50.20 Cr | 4.07 | 119.30 Cr | 0.0909 |
| 2024-12-31 | 438.90 Cr | 210.90 Cr | 228.00 Cr | 0.5195 | 38.90 Cr | 17.20 Cr | 1.39 | 75.70 Cr | 0.0392 |
| 2024-09-30 | 450.80 Cr | 201.90 Cr | 248.90 Cr | 0.5521 | 43.20 Cr | 18.30 Cr | 1.48 | 75.30 Cr | 0.0406 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 13.40 Cr | 46.00 Cr | 59.40 Cr | 282.50 Cr | 414.90 Cr | 820.30 Cr | 1,467.30 Cr | 2,349.10 Cr | 1,154.80 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 18.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,262.30 Cr |
| 2025-03-31 | 18.00 Cr | 0.00 Cr | 18.00 Cr | 522.90 Cr | 334.50 Cr | 995.40 Cr | 1,477.90 Cr | 2,528.90 Cr | 1,266.60 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 36.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,203.40 Cr |
| 2024-09-30 | 28.50 Cr | 8.00 Cr | 36.50 Cr | 459.20 Cr | 338.30 Cr | 930.40 Cr | 1,467.30 Cr | 2,460.30 Cr | 1,256.90 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -22.40 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 50.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 17.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 18.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 5.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2018-06-22 | June 22, 18 | 3:2 |
| 2015-02-27 | February 27, 15 | 5:1 |
| 2003-09-29 | September 29, 03 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,702.10 | ₹4,083,908,052,437.00 | ₹8,520,437.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,194.00 | ₹1,644,312,384,520.00 | ₹454,214.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,045.00 | ₹1,369,011,804,800.00 | ₹464,524.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,228.90 | ₹1,023,143,048,691.00 | ₹1,521,589.00 |
| Lupin Limited | LUPIN | ₹2,182.00 | ₹996,735,418,000.00 | ₹1,253,009.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹903.40 | ₹909,031,786,566.00 | ₹1,049,855.00 |
| Mankind Pharma Limited | MANKIND | ₹2,162.50 | ₹892,690,968,200.00 | ₹778,689.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,222.10 | ₹709,797,663,468.00 | ₹2,827,581.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,695.00 | ₹680,922,675,000.00 | ₹175,750.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,957.50 | ₹552,408,083,618.00 | ₹535,678.00 |
| Laurus Labs Limited | LAURUSLABS | ₹979.50 | ₹528,789,522,069.00 | ₹1,922,825.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,442.20 | ₹365,892,210,514.00 | ₹207,469.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,880.00 | ₹359,814,597,120.00 | ₹119,908.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,891.10 | ₹303,398,628,500.00 | ₹163,849.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,510.00 | ₹286,254,535,400.00 | ₹123,753.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,349.00 | ₹219,201,935,981.00 | ₹626,248.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,651.00 | ₹216,275,000,000.00 | ₹6,215.00 |
| Eris Lifesciences Limited | ERIS | ₹1,440.00 | ₹196,152,323,040.00 | ₹53,547.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,403.00 | ₹171,959,002,267.00 | ₹34,000.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹792.60 | ₹155,795,932,082.00 | ₹30,716.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹981.50 | ₹155,439,907,662.00 | ₹148,427.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹856.10 | ₹153,335,959,707.00 | ₹580,425.00 |
| Cohance Lifesciences Limited | COHANCE | ₹380.45 | ₹145,547,668,413.00 | ₹277,608.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,889.20 | ₹143,601,296,083.00 | ₹69,835.00 |
| Granules India Limited | GRANULES | ₹571.00 | ₹138,563,836,836.00 | ₹818,443.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹948.00 | ₹116,353,728,000.00 | ₹59,006.00 |
| Viyash Scientific Limited | VIYASH | ₹213.00 | ₹92,911,784,067.00 | ₹1,344,290.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,270.00 | ₹87,478,743,140.00 | ₹18,100.00 |
| Strides Pharma Science Limited | STAR | ₹864.00 | ₹79,637,224,896.00 | ₹549,219.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹795.00 | ₹72,064,598,730.00 | ₹164,370.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.85 | ₹68,413,654,617.00 | ₹130,185.00 |
| FDC Limited | FDC | ₹381.85 | ₹62,169,030,575.00 | ₹47,843.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹300.00 | ₹58,674,544,800.00 | ₹470,464.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹139.00 | ₹45,108,500,732.00 | ₹4,587,147.00 |
| Innova Captab Limited | INNOVACAP | ₹722.05 | ₹41,319,259,984.00 | ₹73,408.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹393.40 | ₹35,905,618,000.00 | ₹260,909.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹329.00 | ₹35,849,572,185.00 | ₹41,120.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹700.05 | ₹35,505,909,455.00 | ₹52,380.00 |
| Suven Life Sciences Limited | SUVEN | ₹149.00 | ₹33,893,626,000.00 | ₹501,998.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,968.80 | ₹32,562,012,732.00 | ₹11,115.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹307.30 | ₹30,816,814,094.00 | ₹41,027.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹410.60 | ₹28,908,600,950.00 | ₹55,027.00 |
Key Executives
Head of IP & Quality, Pharmaceuticals
T. Devanathan
Gender: Not Specified
Year Born:
Senior President of Animal Health & Business Transformation
Anish Dilip Swadi
Gender: male
Year Born:
Founder & Executive Chairman
Jai Vishwanath Hiremath
Gender: male
Year Born: 1948
Chief Financial Officer
Kuldeep Jain
Gender: male
Year Born:
President of Pharmaceuticals Business
Manoj Mehrotra
Gender: male
Year Born: 1962
Company Secretary & Compliance Officer
Rajasekhar Reddy
Gender: male
Year Born:
President of Human Resources
Ratish Jha
Gender: male
Year Born:
MD & Vice Chairman
Sameer Hiremath
Gender: male
Year Born: 1974
Whole Time Director
Sarangan Suresh
Gender: male
Year Born: 1963
President of Crop Protection
Vimal Deep Kulshrestha
Gender: male
Year Born: 1965
FAQs about Hikal Limited
Who is the CEO of the company?
The CEO is Jai Vishwanath Hiremath.
What is the current market price of the stock?
The current price is ₹195.69.
What is the 52-week price range?
The range is ₹182-456.75.
What is the market capitalization of the company?
The market capitalization is ₹2,412.87 crores.
What is the dividend yield?
The dividend yield is 0.72%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 238.94.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Hikal Limited (ISIN: INE475B01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,412.87 crores and an average daily volume of 1,570,800 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.4.